Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vivos Therapeutics (VVOS) Operating Expenses (2020 - 2025)

Vivos Therapeutics' Operating Expenses history spans 6 years, with the latest figure at $9.4 million for Q4 2025.

  • Quarterly results put Operating Expenses at $9.4 million for Q4 2025, up 91.11% from a year ago — trailing twelve months through Dec 2025 was $30.4 million (up 50.78% YoY), and the annual figure for FY2025 was $30.4 million, up 50.75%.
  • Operating Expenses for Q4 2025 was $9.4 million at Vivos Therapeutics, up from $8.7 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $10.5 million in Q4 2021 to a low of $4.6 million in Q2 2024.
  • The 5-year median for Operating Expenses is $7.2 million (2023), against an average of $7.2 million.
  • The sharpest move saw Operating Expenses surged 97.43% in 2021, then tumbled 31.84% in 2023.
  • Year by year, Operating Expenses stood at $10.5 million in 2021, then decreased by 19.69% to $8.4 million in 2022, then fell by 26.34% to $6.2 million in 2023, then dropped by 21.2% to $4.9 million in 2024, then surged by 91.11% to $9.4 million in 2025.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $9.4 million, $8.7 million, and $7.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.